LEXINGTON, Mass.— Aldeyra Therapeutics, Inc. (Nasdaq: ALDX), a biotechnology company focused on developing therapies for immune-mediated and metabolic diseases, has appointed Chip Clark to its board of directors.
Clark brings over 30 years of experience in the biopharmaceutical industry and currently serves as co-founder and CEO of Vibrant Biomedicines, a venture-backed company developing vaccines against bacterial pathogens. His leadership background includes previous roles as CEO of Genocea Biosciences and Chief Business Officer at Vanda Pharmaceuticals, which he co-founded. Earlier in his career, Clark was a principal at Care Capital and held various management positions over a decade at SmithKline Beecham, now part of GlaxoSmithKline.
“Chip possesses a wealth of experience leading innovative biotechnology companies,” said Richard H. Douglas, Ph.D., chairman of Aldeyra’s board. “We look forward to leveraging his expertise as Aldeyra continues to advance a pipeline focused on addressing significant unmet medical needs.”
Clark holds an MBA from The Wharton School at the University of Pennsylvania and a bachelor’s degree from Harvard University.
“Aldeyra’s diversified pipeline represents novel approaches to treating a range of serious conditions,” Clark said in a statement. “I’m excited to join the board as the company continues its mission to provide new therapeutic options to patients and healthcare providers.”
